Cargando…

Seroprevalence of Anti-SARS-CoV-2 IgG Antibodies among HIV Infected Individuals Attending ART Centre at Pune: A Cross-Sectional Study

Background: We aimed to determine the anti-SARS-CoV-2 IgG antibodies among people living with HIV (PLHIV) in Pune, India. Methods: This cross-sectional study was conducted between March 2021 and June 2021. Demographic and clinical information related to coronavirus disease 2019 (COVID-19) were recor...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghate, Manisha, Shidhaye, Pallavi, Gurav, Shraddha, Gadhe, Keshav, Kale, Varsha, Jain, Preeti, Thakar, Madhuri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832581/
https://www.ncbi.nlm.nih.gov/pubmed/35128977
http://dx.doi.org/10.1177/23259582221077943
_version_ 1784648751379382272
author Ghate, Manisha
Shidhaye, Pallavi
Gurav, Shraddha
Gadhe, Keshav
Kale, Varsha
Jain, Preeti
Thakar, Madhuri
author_facet Ghate, Manisha
Shidhaye, Pallavi
Gurav, Shraddha
Gadhe, Keshav
Kale, Varsha
Jain, Preeti
Thakar, Madhuri
author_sort Ghate, Manisha
collection PubMed
description Background: We aimed to determine the anti-SARS-CoV-2 IgG antibodies among people living with HIV (PLHIV) in Pune, India. Methods: This cross-sectional study was conducted between March 2021 and June 2021. Demographic and clinical information related to coronavirus disease 2019 (COVID-19) were recorded on structured questionnaires. Blood samples were collected and tested for anti-SARS-CoV-2 IgG antibodies using commercial ELISA. Results: Of the 405 HIV infected individuals enrolled in the study, 223(55.1%) were females. Mean age and CD4 count of participants were 42 years (SD: 10) and 626 cells/mm(3) (SD: 284) respectively. A total of 382 (95%) PLHIV were virologically suppressed. The seropositivity against SARS-CoV-2 was found in 221 PLHIV (54.6%, 95% CI: 49.7-59.4). No significant association was found between demographic or clinical factors and seropositivity. Conclusion: A high prevalence of anti-SARS-CoV-2 IgG antibodies was found among PLHIV attending ART centre indicating an exposure to the virus among them.
format Online
Article
Text
id pubmed-8832581
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-88325812022-02-12 Seroprevalence of Anti-SARS-CoV-2 IgG Antibodies among HIV Infected Individuals Attending ART Centre at Pune: A Cross-Sectional Study Ghate, Manisha Shidhaye, Pallavi Gurav, Shraddha Gadhe, Keshav Kale, Varsha Jain, Preeti Thakar, Madhuri J Int Assoc Provid AIDS Care COVID-19 and the Continuum of HIV Care and Prevention- Original Research Article Background: We aimed to determine the anti-SARS-CoV-2 IgG antibodies among people living with HIV (PLHIV) in Pune, India. Methods: This cross-sectional study was conducted between March 2021 and June 2021. Demographic and clinical information related to coronavirus disease 2019 (COVID-19) were recorded on structured questionnaires. Blood samples were collected and tested for anti-SARS-CoV-2 IgG antibodies using commercial ELISA. Results: Of the 405 HIV infected individuals enrolled in the study, 223(55.1%) were females. Mean age and CD4 count of participants were 42 years (SD: 10) and 626 cells/mm(3) (SD: 284) respectively. A total of 382 (95%) PLHIV were virologically suppressed. The seropositivity against SARS-CoV-2 was found in 221 PLHIV (54.6%, 95% CI: 49.7-59.4). No significant association was found between demographic or clinical factors and seropositivity. Conclusion: A high prevalence of anti-SARS-CoV-2 IgG antibodies was found among PLHIV attending ART centre indicating an exposure to the virus among them. SAGE Publications 2022-02-07 /pmc/articles/PMC8832581/ /pubmed/35128977 http://dx.doi.org/10.1177/23259582221077943 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle COVID-19 and the Continuum of HIV Care and Prevention- Original Research Article
Ghate, Manisha
Shidhaye, Pallavi
Gurav, Shraddha
Gadhe, Keshav
Kale, Varsha
Jain, Preeti
Thakar, Madhuri
Seroprevalence of Anti-SARS-CoV-2 IgG Antibodies among HIV Infected Individuals Attending ART Centre at Pune: A Cross-Sectional Study
title Seroprevalence of Anti-SARS-CoV-2 IgG Antibodies among HIV Infected Individuals Attending ART Centre at Pune: A Cross-Sectional Study
title_full Seroprevalence of Anti-SARS-CoV-2 IgG Antibodies among HIV Infected Individuals Attending ART Centre at Pune: A Cross-Sectional Study
title_fullStr Seroprevalence of Anti-SARS-CoV-2 IgG Antibodies among HIV Infected Individuals Attending ART Centre at Pune: A Cross-Sectional Study
title_full_unstemmed Seroprevalence of Anti-SARS-CoV-2 IgG Antibodies among HIV Infected Individuals Attending ART Centre at Pune: A Cross-Sectional Study
title_short Seroprevalence of Anti-SARS-CoV-2 IgG Antibodies among HIV Infected Individuals Attending ART Centre at Pune: A Cross-Sectional Study
title_sort seroprevalence of anti-sars-cov-2 igg antibodies among hiv infected individuals attending art centre at pune: a cross-sectional study
topic COVID-19 and the Continuum of HIV Care and Prevention- Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832581/
https://www.ncbi.nlm.nih.gov/pubmed/35128977
http://dx.doi.org/10.1177/23259582221077943
work_keys_str_mv AT ghatemanisha seroprevalenceofantisarscov2iggantibodiesamonghivinfectedindividualsattendingartcentreatpuneacrosssectionalstudy
AT shidhayepallavi seroprevalenceofantisarscov2iggantibodiesamonghivinfectedindividualsattendingartcentreatpuneacrosssectionalstudy
AT guravshraddha seroprevalenceofantisarscov2iggantibodiesamonghivinfectedindividualsattendingartcentreatpuneacrosssectionalstudy
AT gadhekeshav seroprevalenceofantisarscov2iggantibodiesamonghivinfectedindividualsattendingartcentreatpuneacrosssectionalstudy
AT kalevarsha seroprevalenceofantisarscov2iggantibodiesamonghivinfectedindividualsattendingartcentreatpuneacrosssectionalstudy
AT jainpreeti seroprevalenceofantisarscov2iggantibodiesamonghivinfectedindividualsattendingartcentreatpuneacrosssectionalstudy
AT thakarmadhuri seroprevalenceofantisarscov2iggantibodiesamonghivinfectedindividualsattendingartcentreatpuneacrosssectionalstudy